Pfizer, P&G down on drug ban; overall weakness in pharma stock

March 15, 2016 07:12 pm | Updated September 06, 2016 12:27 pm IST - Mumbai

Shares of Pfizer and Procter and Gamble (P&G) today fell by about 3 per cent amid concerns over ban on their popular drug products.

Stock prices of a number of pharma companies were also down, leading to overall decline of more than 3 per cent in the sectoral index.

Pfizer’s scrip went down by 3.15 per cent to close at Rs 1,705.30 on BSE, as the company has discontinued manufacture and sale of popular cough syrup Corex with immediate effect.

During the day, it had slipped 3.81 per cent to Rs 1,693.60, its 52-week low.

Shares of Pfizer had slumped 9 per cent in the previous session also.

>P&G’s scrip fell by 0.99 per cent to settle at Rs 6,067.85 as the company discontinued manufacture and sale of its popular brand ‘Vicks Action 500 Extra’ with immediate effect, after the government banned fixed dose combination drugs. Intra-day, the stock lost 2.49 per cent to Rs. 5,975.35.

The Delhi High Court yesterday granted interim stay of notification restraining sale of pharma major Pfizer’s cough syrup ‘Corex’ and directed the government not to take coercive steps against the company.

Reflecting overall weak sentiment for the sector, selling was also seen in other pharma stocks where Anuh Pharma tanked 9.84 per cent, Marksans Pharma dived 5.59 per cent, Nectar Lifesciences (5.40 per cent), Unichem Lab (5.08 per cent), Divis Lab (5.06 per cent), Dishman Pharma (4.76 per cent) and Jubilant Life Sciences (4.55 per cent).

Led by the sharp decline in these stocks, the BSE healthcare index slumped 3.01 per cent to end at 15,541.47.

In broader market, the BSE index, Sensex, was down over 253 points at 24,551.17.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.